FGFR2 and cancer: Treatment with regorafenib effectively inhibited cellular growth and phosphorylation of FGFR2 and its downstream signaling molecules in a dose‐dependent manner and selectively in FGFR2‐amplified cancer cell lines (Fig. 4A, B).